IGM Biosciences (NASDAQ:IGMS) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.80) by 26.25 percent. The company reported quarterly sales of $516.000 thousand which beat the analyst consensus estimate of $267.222 thousand by 93.10 percent. This is a 1.38 percent increase over sales of $509.000 thousand the same period last year.